日本語 / English

DefiniGEN Ltd.

 

DefiniGEN was founded in April 2013 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK.

 

The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.

 

DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and in addition has in-licensed the Yamanaka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.

 

 

News & topics

Information

Category

iPS, Regenerative medicine, Differentiation, Hepatocyte, Pancreatic beta cells, Intestinal Organoids, Disease modelling, Drug Discovery

 

Business model

Production of iPS-differentiated cells (cryo-preserved)

Custom gene-editing to derive specific disease modells

Custom project (iPS-reprogramming & differentiation)

 

 

Relationship to Biospire

Business development support to the global market.

 


Location

Babraham Research Campus

Cambridge

CB22 3AT

U.K.

Email: masashi@definigen.com

Telephone: 050-5534-0777